SCHEMBL524564

SCHEMBL524564

C[C@H](Cc1cc(C#N)c2c(c1)CCN2CCCOC(=O)c1ccccc1)NCCOc1ccccc1OCC(F)(F)F

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 20/20 0.64
ADRA1D P25100 19/20 0.64
ADRA1B P35368 19/20 0.64
HTR1A P08908 2/20 0.64
ADRA2A P08913 2/20 0.64
ADRA2B P18089 2/20 0.64
ADRA2C P18825 2/20 0.64
HRH1 P35367 2/20 0.64
OPRM1 P35372 2/20 0.64
DRD3 P35462 2/20 0.64
HTR2B P41595 2/20 0.64
SLC6A3 Q01959 2/20 0.64
KCNH2 Q12809 2/20 0.64
ADRB2 P07550 1/20 0.64
DRD2 P14416 1/20 0.64
DRD1 P21728 1/20 0.64
DRD4 P21917 1/20 0.64
PTGS1 P23219 1/20 0.64
HTR1D P28221 1/20 0.64
HTR1B P28222 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13729913 1.00 ADRA1A (0.64) ADRA1AADRA1DADRA1BHTR1AADRA2A
SCHEMBL28926323 1.00 ADRA1A (0.64) ADRA1AADRA1DADRA1BHTR1AADRA2A
Oxalic Acid SCHEMBL526172 0.99 ADRA1A (0.62) ADRA1AADRA1DADRA1BHTR1AADRA2A
Oxalic Acid SCHEMBL28644141 0.99 ADRA1A (0.62) ADRA1AADRA1DADRA1BHTR1AADRA2A
Oxalic Acid SCHEMBL28644138 0.99 ADRA1A (0.62) ADRA1AADRA1DADRA1BHTR1AADRA2A
SCHEMBL18157802 0.96 ADRA1D (0.62) ADRA1AADRA1DADRA1BHTR1AADRA2A
Alpha-Ketoglutaric Acid SCHEMBL17026691 0.94 ADRA1D (0.58) ADRA1AADRA1DADRA1BHTR1AADRA2A
SCHEMBL13037438 0.92 ADRA1A (0.59) ADRA1AADRA1DADRA1BHTR1AADRA2A
SCHEMBL28996811 0.92 ADRA1D (0.66) ADRA1AADRA1DADRA1BHTR1AADRA2A
SCHEMBL19730677 0.92 ADRA1D (0.55) ADRA1AADRA1DADRA1BHTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012147107-A2 NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION MSN LABORATORIES LIMITED (IN) 2012-11-01 WO claimed
EP-1806340-B1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME KISSEI PHARMACEUTICAL (JP) 2011-05-04 EP claimed
US-7834193-B2 Indoline compound and process for producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US claimed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US claimed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP claimed
CN-111217735-B Preparation method of silodosin intermediate 上海汇伦医药股份有限公司 2023-03-14 CN disclosed
EP-3357907-B1 MALEIC ACID SALT OF A SILODOSIN INTERMEDIATE URQUIMA SA (ES) 2022-11-30 EP disclosed
WO-2020237645-A1 PREPARATION METHOD FOR SILODOSIN INTERMEDIATE 上海汇伦生命科技有限公司 2020-12-03 WO disclosed
CN-111217735-A Preparation method of silodosin intermediate 上海汇伦医药科技有限公司 2020-06-02 CN disclosed
US-10421719-B2 Maleic acid salt of a silodosin intermediate URQUIMA S.A. (ES) 2019-09-24 US disclosed
US-10421719-B2 Maleic acid salt of a silodosin intermediate URQUIMA S.A. (ES) 2019-09-24 US disclosed
US-10377710-B2 Process for the preparation of considerably pure Silodosin MANKIND PHARMA LTD. (IN) 2019-08-13 US disclosed
US-7834193-B2 Indoline compound and process for producing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-11-16 US disclosed
CN-101048376-A Indoline compound and process for producing the same KISSEI PHARMACEUTICAL (JP) 2007-10-03 CN disclosed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US disclosed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US disclosed
US-20070197627-A1 Indoline compound and process for producting the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 US disclosed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP disclosed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP disclosed
EP-1806340-A1 INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421719-B2 Maleic acid salt of a silodosin intermediate MEP1A, PTMA, MSMO1 ADRA1A 670/4885ADRA1D 549/4885ADRA1B 1114/4885
US-10377710-B2 Process for the preparation of considerably pure Silodosin CYP51A1, LSS, SRI ADRA1A 646/4885ADRA1D 378/4885ADRA1B 557/4885
US-20070197627-A1 Indoline compound and process for producting the same BPHL, DAO, INHA ADRA1A 1628/4885ADRA1D 369/4885ADRA1B 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.